Skip to content
Sunday 16 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sunday 21 January 2024 4:30 pm

Experts warn weight-loss drug Ozempic is causing wave of loose skin surgeries

By: Laura Forsyth

Add as a preferred source on Google
Worryingly, consumer searches for weight loss jabs and pens are also on the rise despite the market being largely unregulated
Worryingly, consumer searches for weight loss jabs and pens are also on the rise despite the market being largely unregulated

Diabetes medication Ozempic has come under scrutiny for its reported association with a significant increase in loose skin surgeries.

Initially approved by the Food and Drug Administration (FDA) in 2017 as an injectable solution for adults struggling with inadequately controlled type 2 diabetes, Ozempic has since expanded its usage to include obesity treatment.

The drug, containing the active substance semaglutide, gained notable attention for its impact on weight loss, with reports surfacing on popular social media platforms such as TikTok. The hashtag #Ozempic on TikTok alone has garnered over 273 million views, contributing to a substantial uptick in prescriptions. Healthcare providers issued over 9 million prescriptions in the final quarter of 2022, indicating a surge in its popularity.

Sales figures for Ozempic in the United States exceeded $8.5bn (£6.7bn) in 2022, constituting a significant portion of global sales, amounting to 65 per cent. Projections suggest continued growth, with anticipated annual sales reaching $12.5 (£9.8bn) in 2023 and a staggering $17bn (£13.3bn) by 2029.

Despite its commercial success, Ozempic is not without its drawbacks. Concerns have been raised about its impact on facial fat and the rapid weight loss it induces. Dermatological changes, including an increase in signs of ageing such as lines and wrinkles (referred to as “Ozempic face”), a hollowed-out appearance, and lipodystrophy, have been reported.

Gediminas Samulenas, a surgeon at Nordesthetics clinic in Kaunas, Lithuania, shed light on the issue. “The active substance of Ozempic is semaglutide, which has absolutely zero direct impact on the skin. It acts by altering insulin-glucose metabolism, leading to weight loss followed by a reduction of facial volume and a relative increase in loose skin. But there is no actual effect on the skin; its laxity and looseness is a consequence of weight loss,” he explained.

Nordesthetics Clinic has reported a notable surge in visits from UK patients seeking solutions for excess skin resulting from various weight loss methods, including Ozempic. One such case saw a woman, who underwent bariatric surgery followed by a tummy tuck procedure to address the extra skin after a rapid loss of body mass.

Experts at the clinic emphasise the importance of recognising that individuals undergoing weight loss, whether through Ozempic or other means, often require excess skin removal to fully realize the benefits of their weight loss journey.

Despite these concerns, Ozempic remains a positive method for addressing obesity, contributing to weight loss by curbing hunger, prolonging the time it takes for the stomach to empty, and lowering blood sugar levels.

However, the surge in loose skin surgeries underscores the need for caution and careful consideration of potential side effects associated with the medication.

Read more

Fine dining and The Jab: A Michelin dinner with the Ozempic set

Ozempic tablet on a plate highlighting medications role in weight loss and diabetes management in healthcare news.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Life&Style

Categories

  • Wellness

Related Topics

  • Health

Trending Articles

  • Grandparents fund university degrees to avoid inheritance tax net

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut takes flight with launch of new airport lounges

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

More from Morning Wire

  • Fine dining and The Jab: A Michelin dinner with the Ozempic set

    Life&Style
    Ozempic tablet on a plate highlighting medications role in weight loss and diabetes management in healthcare news.
  • Terry Smith dubs weight-loss giant Novo Nordisk ‘investment disaster’

    Investing
    Terry Smith, founder of Fundsmith, speaking at a business conference, wearing a suit and tie, with a focused expression.
  • Bonheur by Matt Abé review: This Michelin magnet left me hungry

    Life&Style
    Elegant restaurant interior with round tables, plush burgundy booths, and textured floral wall art
  • Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

    Business Wire
  • This Is the Moment Everything Changed: Ascensia Launches Global Art and Photography Competition for World Diabetes Day

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook